RxDoctor Payments Data

Maria Frisch, MD

Family Medicine · Greer, SCNPI 1639181662

Payments from drug & device makers

$1,381in general payments, 2019–2025

Across 136 payments — averaging $10.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$581
  • Novo Nordisk$177
  • Johnson & Johnson$113
  • Pfizer$111
  • Lilly USA, LLC$98
  • AstraZeneca$88
  • plus $215 from 9 others

What the payments were for

  • Food & beverage$1,381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,381 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$19,618
Medicare patients
49
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$97,347
JardianceEmpagliflozin84$95,916
FarxigaDapagliflozin Propanediol56$66,825
OzempicSemaglutide42$49,815
LinzessLinaclotide49$43,150
MyrbetriqMirabegron28$24,283
TrintellixVortioxetine Hydrobromide30$22,938
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$20,640
EliquisApixaban25$19,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,636
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$12,541
TradjentaLinagliptin15$10,811
Dexlansoprazole DrDexlansoprazole15$7,509
VascepaIcosapent Ethyl17$6,139
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$98$97,34784 claims
AstraZenecaFarxiga$88$66,82556 claims
Novo NordiskOzempic$177$49,81542 claims
AbbVieLinzess, Synthroid$581$45,63767 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant$32$26,93241 claims
Astellas Pharma US IncMyrbetriq$18$24,28328 claims
PfizerEliquis$111$19,66225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →